New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications

FEBS Letters

Volumn 582, Issue 6, 2008, Pages 844-847

  Sannella, Anna Rosa ^a   Casini, Angela ^b   Gabbiani, Chiara ^b   Messori, Luigi ^b   Bilia, Anna Rita ^b   Vincieri, Francesco Franco ^b   Majori, Giancarlo ^a   Severini, Carlo ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Gold drugs; Malaria; Plasmodium falciparum; Thioredoxin reductase

Indexed keywords

ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; ARTEMISININ; AURANOFIN; AUROTHIOMALATE; CYCLAM DERIVATIVE; ENZYME INHIBITOR; GOLD COMPLEX; GOLD CYCLAM; THIOL GROUP; THIOREDOXIN REDUCTASE; TRIETHYLPHOSPHINE GOLD; UNCLASSIFIED DRUG;

ANTIMALARIAL ACTIVITY; ARTICLE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME INHIBITION; IN VITRO STUDY; NONHUMAN; OXIDATIVE STRESS; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ANIMALIA; MAMMALIA; PLASMODIUM FALCIPARUM;

EID: 40149085227     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2008.02.028     Document Type: Article

References (26)

1. L. Messori G. Marcon Gold complexes in the treatment of rheumatoid arthritis Met. Ions Biol. Syst. 41 2004 279 304
2. C.F. Shaw III Gold-based therapeutics agents Chem. Rev. 99 1999 2589 2600
3. W.F. Kean L. Hart W.W. Buchannan Auranofin Br. J. Rheum. 36 1997 560 572
4. S. Havarinasab U. Johansson K.M. Pollard P. Hultman Gold causes genetically determined autoimmune and immunostimulatory responses in mice Clin. Exp. Immunol. 150 2007 179 188
5. R. Eisler Chrysotherapy: a synoptic review Inflam. Res. 52 2003 487 501
6. A. Chircorian A.M. Barrios Inhibition of lysosomal cysteine proteases by chrysotherapeutic compounds: a possible mechanism for the antiarthritic activity of Au(I) Bioorg. Med. Chem. Lett. 14 2004 5113 5116
7. E. Weidauer Y. Yasuda B.K. Biswal M. Cherny M.N. James D. Bromme Effects of disease modifying anti-rheumatic drugs (DMARDs) on the activities of rheumatoid arthritis-associated cathepsins K and S Biol. Chem. 388 2007 331 336
8. S. Gromer L.D. Arscott C.H. Williams Jr. R.H. Schirmer K. Becker Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds J. Biol. Chem. 273 1998 20096 20101
9. M.P. Rigobello G. Scutari R. Boscolo A. Bindoli Induction of mitochondrial permeability transition by auranofin, a gold(I)–phosphine derivative Br. J. Pharmacol. 136 2002 1162 1168
10. M.P. Rigobello L. Messori G. Marcon M.A. Cinellu M. Bragadin A. Folda G. Scutari A. Bindoli Gold complexes inhibit mitochondrial thioredoxin reductase: consequences on mitochondrial functions J. Inorg. Biochem. 98 2004 1634 1641
11. M.H. Yoo X.M. Xu B.A. Carlson V.N. Gladyshev D.L. Hatfield Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells J. Biol. Chem. 281 2006 13005 13008
12. J. Lu E.H. Chew S. Holmgren A. Targeting TrxR is a basis for cancer therapy by arsenic trioxide Proc. Natl. Acad. Sci. USA 104 2007 12288 12293 (This paper strongly suggests that the anticancer activity of arsenic trioxide is by means of a Trx system-mediated apoptosis. This new article reinforces the view that thioredoxin reductase represents today an important cancer target).
13. K. Becker S. Gromer R.H. Schirmer S. Müller Thioredoxin reductase as a pathophysiological factor and drug target Eur. J. Biochem. 267 2000 6118 6125
14. See for example the website .
15. T. Jaeger L. Flohe The thiol-based redox networks of pathogens: unexploited targets in the search for new drugs Biofactors 27 2006 109 120
16. C. Nickel S. Rahlfs M. Deponte S. Koncarevic K. Becker Thioredoxin networks in the malarial parasite Plasmodium falciparum Antioxid. Redox Signal. 8 2006 1227 1239
17. R.A. Sánchez-Delgado A. Anzellotti Metal complexes as chemotherapeutic agents against tropical diseases: trypanosomiasis, malaria and leishmaniasis Mini Rev. Med. Chem. 4 2004 23 30
18. T. Makler R.C. Piper W.K. Milhous Lactate dehydrogenase and the diagnosis of malaria Parasitol. Today 14 1998 376 377
19. L. Messori F. Abbate G. Marcon P. Orioli M. Fontani E. Mini T. Mazzei S. Carotti T. O’Connell P. Zanello Gold(III) complexes as potential antitumor agents: solution chemistry and cytotoxic properties of some selected gold(III) compounds J. Med. Chem. 43 2000 3541 3548
20. J.D. Herrlinger C. Alsen R. Beress U. Hecker W. Weikert Distribution of gold in serum erythrocytes and white blood cells after in vitro incubation and during chrysotherapy with different gold compounds J. Rheumatol. Suppl. 8 1982 81 89
21. P.M. O’Neill G.H. Posner A medicinal chemistry perspective on artemisinin and related endoperoxides J. Med. Chem. 47 2004 2945 2964
22. S.R. Krungkrai Y. Yuthavong The antimalarial action on Plasmodium falciparum of qinghaosu and artesunate in combination with agents which modulate oxidant stress Trans. R. Soc. Trop. Med. Hyg. 81 1987 710 714
23. M.C. Berenbaum A method for testing for synergy with any number of agents J. Infect. Dis. 137 1978 122 130
24. A. Bell Antimalarial drug synergism and antagonism. Mechanistic and clinical significance FEMS Microbiol. Lett. 253 2005 171 184
25. C.R. Chong D.J. Sullivan Jr. New uses for old drugs Nature 448 7154 2007 645 646
26. During the preparation of this manuscript, a new article has appeared detailing the effectiveness of auranofin in the treatment of another important parasitic disease, schistosomiasis A.N. Kuntz E. Davioud-Charvet A.A. Sayed L.L. Califf J. Dessolin E.S. Arnér D.L. Williams Thioredoxin glutathione reductase from Schistosoma mansoni : an essential parasite enzyme and a key drug target PLoS Med. 4 2007 e206 (This additional finding gives further support to the idea that an established drug such as auranofin, in view of its peculiar reactivity, may be conveniently used for therapeutic indications other than the original one).